Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Premal H. Thaker, MD, MS
Advertisement
Articles by Premal H. Thaker, MD, MS
Advertisement
Latest Updated Articles
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer SubgroupPublished: June 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
Novel Cancer Vaccine Improves OS vs SOC in Newly Diagnosed GBM
4
Silevertinib Displays Robust Antitumor Activity in EGFR-Mutated NSCLC
5
